The role of the Nrf2/GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours

Purpose Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very poor prognosis. Chemoresistance is a major issue in the treatment of this malignancy leading to an urgent need for a greater understa...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of cancer research and clinical oncology Ročník 149; číslo 11; s. 8379 - 8391
Hlavní autori:	Hannon Barroeta, Patricia, O’Sullivan, Maureen J., Zisterer, Daniela M.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2023 Springer Nature B.V
Predmet:	Acetylcysteine antioxidant activity Antioxidants Antioxidants - pharmacology Apoptosis Buthionine Sulfoximine Cancer Research Cancer therapies cancer therapy Cell Line, Tumor Central nervous system Chemoresistance Chemotherapy Child childhood Children Cisplatin Cisplatin - pharmacology drug therapy Glutathione Glutathione - metabolism Hematology Humans Internal Medicine Malignancy Medicine Medicine & Public Health neoplasms NF-E2-Related Factor 2 - metabolism Oncology Oxidative stress prognosis Reactive oxygen species Reactive Oxygen Species - metabolism Rhabdoid Tumor - drug therapy siRNA transcription factors Tumors Reactive oxygen species Nuclear erythroid-related factor-2 Malignant rhabdoid tumour Chemoresistance Apoptosis Glutathione
ISSN:	0171-5216, 1432-1335, 1432-1335
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Purpose Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very poor prognosis. Chemoresistance is a major issue in the treatment of this malignancy leading to an urgent need for a greater understanding of its underlying mechanisms in MRT and novel treatment strategies for MRT patients. The balance between oxidative stress mediated by reactive oxygen species (ROS) and the antioxidant system has become a subject of interest in cancer therapy research. Studies have implicated key players of the antioxidant system in chemotherapeutic including the well-known antioxidant glutathione (GSH) and the transcription factor nuclear erythroid-related factor-2 (Nrf2). Methods This study evaluated the role of these components in the response of MRT cells to treatment with the commonly used chemotherapeutic agent, cisplatin. Results This study characterised the basal levels of GSH, ROS and Nrf2 in a panel of MRT cell lines and found a correlation between the expression profile of the antioxidant defence system and cisplatin sensitivity. Results showed that treatment with ROS scavenger N-acetylcysteine (NAC) protected cells from cisplatin-induced ROS and apoptosis. Interestingly, depleting GSH levels with the inhibitor buthionine sulphoximine (BSO) enhanced cisplatin-induced ROS and sensitised cells to cisplatin. Lastly, targeting Nrf2 with the small molecule inhibitor ML385 or by siRNA diminished GSH levels, enhanced ROS and sensitised resistant MRT cells to cisplatin. Conclusions These results suggest that targeting the Nrf2/GSH antioxidant system may present a novel therapeutic strategy to combat chemoresistance in rhabdoid tumours.
AbstractList	Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very poor prognosis. Chemoresistance is a major issue in the treatment of this malignancy leading to an urgent need for a greater understanding of its underlying mechanisms in MRT and novel treatment strategies for MRT patients. The balance between oxidative stress mediated by reactive oxygen species (ROS) and the antioxidant system has become a subject of interest in cancer therapy research. Studies have implicated key players of the antioxidant system in chemotherapeutic including the well-known antioxidant glutathione (GSH) and the transcription factor nuclear erythroid-related factor-2 (Nrf2). METHODS: This study evaluated the role of these components in the response of MRT cells to treatment with the commonly used chemotherapeutic agent, cisplatin.PURPOSEMalignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very poor prognosis. Chemoresistance is a major issue in the treatment of this malignancy leading to an urgent need for a greater understanding of its underlying mechanisms in MRT and novel treatment strategies for MRT patients. The balance between oxidative stress mediated by reactive oxygen species (ROS) and the antioxidant system has become a subject of interest in cancer therapy research. Studies have implicated key players of the antioxidant system in chemotherapeutic including the well-known antioxidant glutathione (GSH) and the transcription factor nuclear erythroid-related factor-2 (Nrf2). METHODS: This study evaluated the role of these components in the response of MRT cells to treatment with the commonly used chemotherapeutic agent, cisplatin.This study characterised the basal levels of GSH, ROS and Nrf2 in a panel of MRT cell lines and found a correlation between the expression profile of the antioxidant defence system and cisplatin sensitivity. Results showed that treatment with ROS scavenger N-acetylcysteine (NAC) protected cells from cisplatin-induced ROS and apoptosis. Interestingly, depleting GSH levels with the inhibitor buthionine sulphoximine (BSO) enhanced cisplatin-induced ROS and sensitised cells to cisplatin. Lastly, targeting Nrf2 with the small molecule inhibitor ML385 or by siRNA diminished GSH levels, enhanced ROS and sensitised resistant MRT cells to cisplatin.RESULTSThis study characterised the basal levels of GSH, ROS and Nrf2 in a panel of MRT cell lines and found a correlation between the expression profile of the antioxidant defence system and cisplatin sensitivity. Results showed that treatment with ROS scavenger N-acetylcysteine (NAC) protected cells from cisplatin-induced ROS and apoptosis. Interestingly, depleting GSH levels with the inhibitor buthionine sulphoximine (BSO) enhanced cisplatin-induced ROS and sensitised cells to cisplatin. Lastly, targeting Nrf2 with the small molecule inhibitor ML385 or by siRNA diminished GSH levels, enhanced ROS and sensitised resistant MRT cells to cisplatin.These results suggest that targeting the Nrf2/GSH antioxidant system may present a novel therapeutic strategy to combat chemoresistance in rhabdoid tumours.CONCLUSIONSThese results suggest that targeting the Nrf2/GSH antioxidant system may present a novel therapeutic strategy to combat chemoresistance in rhabdoid tumours. Purpose Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very poor prognosis. Chemoresistance is a major issue in the treatment of this malignancy leading to an urgent need for a greater understanding of its underlying mechanisms in MRT and novel treatment strategies for MRT patients. The balance between oxidative stress mediated by reactive oxygen species (ROS) and the antioxidant system has become a subject of interest in cancer therapy research. Studies have implicated key players of the antioxidant system in chemotherapeutic including the well-known antioxidant glutathione (GSH) and the transcription factor nuclear erythroid-related factor-2 (Nrf2). Methods This study evaluated the role of these components in the response of MRT cells to treatment with the commonly used chemotherapeutic agent, cisplatin. Results This study characterised the basal levels of GSH, ROS and Nrf2 in a panel of MRT cell lines and found a correlation between the expression profile of the antioxidant defence system and cisplatin sensitivity. Results showed that treatment with ROS scavenger N-acetylcysteine (NAC) protected cells from cisplatin-induced ROS and apoptosis. Interestingly, depleting GSH levels with the inhibitor buthionine sulphoximine (BSO) enhanced cisplatin-induced ROS and sensitised cells to cisplatin. Lastly, targeting Nrf2 with the small molecule inhibitor ML385 or by siRNA diminished GSH levels, enhanced ROS and sensitised resistant MRT cells to cisplatin. Conclusions These results suggest that targeting the Nrf2/GSH antioxidant system may present a novel therapeutic strategy to combat chemoresistance in rhabdoid tumours. PurposeMalignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very poor prognosis. Chemoresistance is a major issue in the treatment of this malignancy leading to an urgent need for a greater understanding of its underlying mechanisms in MRT and novel treatment strategies for MRT patients. The balance between oxidative stress mediated by reactive oxygen species (ROS) and the antioxidant system has become a subject of interest in cancer therapy research. Studies have implicated key players of the antioxidant system in chemotherapeutic including the well-known antioxidant glutathione (GSH) and the transcription factor nuclear erythroid-related factor-2 (Nrf2). MethodsThis study evaluated the role of these components in the response of MRT cells to treatment with the commonly used chemotherapeutic agent, cisplatin.ResultsThis study characterised the basal levels of GSH, ROS and Nrf2 in a panel of MRT cell lines and found a correlation between the expression profile of the antioxidant defence system and cisplatin sensitivity. Results showed that treatment with ROS scavenger N-acetylcysteine (NAC) protected cells from cisplatin-induced ROS and apoptosis. Interestingly, depleting GSH levels with the inhibitor buthionine sulphoximine (BSO) enhanced cisplatin-induced ROS and sensitised cells to cisplatin. Lastly, targeting Nrf2 with the small molecule inhibitor ML385 or by siRNA diminished GSH levels, enhanced ROS and sensitised resistant MRT cells to cisplatin.ConclusionsThese results suggest that targeting the Nrf2/GSH antioxidant system may present a novel therapeutic strategy to combat chemoresistance in rhabdoid tumours. Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very poor prognosis. Chemoresistance is a major issue in the treatment of this malignancy leading to an urgent need for a greater understanding of its underlying mechanisms in MRT and novel treatment strategies for MRT patients. The balance between oxidative stress mediated by reactive oxygen species (ROS) and the antioxidant system has become a subject of interest in cancer therapy research. Studies have implicated key players of the antioxidant system in chemotherapeutic including the well-known antioxidant glutathione (GSH) and the transcription factor nuclear erythroid-related factor-2 (Nrf2). METHODS: This study evaluated the role of these components in the response of MRT cells to treatment with the commonly used chemotherapeutic agent, cisplatin. This study characterised the basal levels of GSH, ROS and Nrf2 in a panel of MRT cell lines and found a correlation between the expression profile of the antioxidant defence system and cisplatin sensitivity. Results showed that treatment with ROS scavenger N-acetylcysteine (NAC) protected cells from cisplatin-induced ROS and apoptosis. Interestingly, depleting GSH levels with the inhibitor buthionine sulphoximine (BSO) enhanced cisplatin-induced ROS and sensitised cells to cisplatin. Lastly, targeting Nrf2 with the small molecule inhibitor ML385 or by siRNA diminished GSH levels, enhanced ROS and sensitised resistant MRT cells to cisplatin. These results suggest that targeting the Nrf2/GSH antioxidant system may present a novel therapeutic strategy to combat chemoresistance in rhabdoid tumours. PURPOSE: Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very poor prognosis. Chemoresistance is a major issue in the treatment of this malignancy leading to an urgent need for a greater understanding of its underlying mechanisms in MRT and novel treatment strategies for MRT patients. The balance between oxidative stress mediated by reactive oxygen species (ROS) and the antioxidant system has become a subject of interest in cancer therapy research. Studies have implicated key players of the antioxidant system in chemotherapeutic including the well-known antioxidant glutathione (GSH) and the transcription factor nuclear erythroid-related factor-2 (Nrf2). METHODS: This study evaluated the role of these components in the response of MRT cells to treatment with the commonly used chemotherapeutic agent, cisplatin. RESULTS: This study characterised the basal levels of GSH, ROS and Nrf2 in a panel of MRT cell lines and found a correlation between the expression profile of the antioxidant defence system and cisplatin sensitivity. Results showed that treatment with ROS scavenger N-acetylcysteine (NAC) protected cells from cisplatin-induced ROS and apoptosis. Interestingly, depleting GSH levels with the inhibitor buthionine sulphoximine (BSO) enhanced cisplatin-induced ROS and sensitised cells to cisplatin. Lastly, targeting Nrf2 with the small molecule inhibitor ML385 or by siRNA diminished GSH levels, enhanced ROS and sensitised resistant MRT cells to cisplatin. CONCLUSIONS: These results suggest that targeting the Nrf2/GSH antioxidant system may present a novel therapeutic strategy to combat chemoresistance in rhabdoid tumours.
Author	Hannon Barroeta, Patricia O’Sullivan, Maureen J. Zisterer, Daniela M.
Author_xml	– sequence: 1 givenname: Patricia surname: Hannon Barroeta fullname: Hannon Barroeta, Patricia email: hannonbp@tcd.ie organization: School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin – sequence: 2 givenname: Maureen J. surname: O’Sullivan fullname: O’Sullivan, Maureen J. organization: The National Children’s Research Centre, Children’s Health Ireland at Crumlin – sequence: 3 givenname: Daniela M. surname: Zisterer fullname: Zisterer, Daniela M. organization: School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/37079050$$D View this record in MEDLINE/PubMed
BookMark	eNqFkk1v1DAQhi1URLeFP8ABReLCJXTijzh7QqiCFqmCA-VsOY696yqxF9tB23_PhG356KGcPB4_76uZ8ZyQoxCDJeRlA28bAHmWATijNVBWA5eM1_snZNUsqYYxcURW0MimFrRpj8lJzjeAdyHpM3LMJMg1CFgRfb21VYqjraKrCsafk6NnF18vKx2Kj3s_4Fnl21zsVPlQGZ93oy4YJZt9LjoYu-QnPfpNWNi01f0Q_VCVeYpzys_JU6fHbF_cnafk28cP1-eX9dWXi0_n769qI6ArdcvdoJ0crDAtF63speh63tK208ZYbbTgjnJkXeuYs9RIZ0XHtBOD1A56dkreHXx3cz_ZwdhQkh7VLvlJp1sVtVf_vgS_VZv4QzXAJJfQocObO4cUv882FzX5bOw46mDjnBUDDpxDK9v_orQDtsY-mED09QP0BscScBRIcdqu0XKN1Ku_q_9d9v1PIdAdAJNizsk6ZXzBj4hLM37ELtSyFOqwFAqXQv1aCrVHKX0gvXd_VMQOooxw2Nj0p-xHVD8BucbLWA
CitedBy_id	crossref_primary_10_1016_j_bbrc_2024_150335 crossref_primary_10_3390_cancers16244218 crossref_primary_10_1007_s12017_024_08807_z crossref_primary_10_1186_s41120_025_00107_5 crossref_primary_10_1002_cbin_12248 crossref_primary_10_1186_s11671_025_04248_0 crossref_primary_10_1007_s11033_024_10176_6 crossref_primary_10_3389_fonc_2023_1184079 crossref_primary_10_3390_nu17020267 crossref_primary_10_1073_pnas_2425384122 crossref_primary_10_1096_fj_202501369R crossref_primary_10_3390_ijms251910257
Cites_doi	10.3390/cancers3011351 10.1200/JCO.2005.05.187 10.1158/0008-5472.CAN-07-5840 10.1038/s41598-019-54065-6 10.3109/10715761003667554 10.1371/journal.pone.0081162 10.1021/acschembio.6b00651 10.15430/JCP.2014.19.2.111 10.3390/antiox10040510 10.1089/ars.2017.7342 10.18632/oncotarget.8600 10.1002/jbt.22942 10.3389/fonc.2019.00754 10.3892/ol.2015.3879 10.1083/jcb.201804161 10.1155/2019/3461251 10.1016/j.taap.2021.115646 10.1515/BC.2009.033 10.1002/mc.22615 10.2147/DDDT.S106412 10.1124/mi.7.3.6 10.3109/10408441003601836 10.1016/j.ctarc.2022.100584 10.1155/2013/972913 10.1016/j.cellsig.2012.01.008 10.1042/BJ20130282 10.1038/nrc3278 10.1016/j.ccell.2020.06.001 10.1016/j.cotox.2016.10.001 10.21037/tcr-21-2548 10.1002/pbc.24602 10.1111/jnc.14250 10.1615/CritRevOncog.2015013566 10.1038/bcj.2014.45 10.18632/oncotarget.10129
ContentType	Journal Article
Copyright	The Author(s) 2023 2023. The Author(s). Copyright Springer Nature B.V. Sep 2023
Copyright_xml	– notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: Copyright Springer Nature B.V. Sep 2023
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9. M0S M1P M2O MBDVC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 5PM
DOI	10.1007/s00432-023-04734-x
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Proquest Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic
DatabaseTitleList	MEDLINE - Academic Research Library Prep MEDLINE AGRICOLA
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central (ProQuest) url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1432-1335
EndPage	8391
ExternalDocumentID	PMC10374708 37079050 10_1007_s00432_023_04734_x
Genre	Journal Article
GrantInformation_xml	– fundername: University of Dublin, Trinity College – fundername: ;
GroupedDBID	--- -53 -5E -5G -BR -EM -Y2 -~C -~X .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29K 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8UJ 95- 95. 95~ 96X AAAVM AABHQ AAHNG AAIAL AAJKR AAJSJ AAKKN AANXM AANZL AARHV AARTL AATVU AAUYE AAWCG AAYIU AAYOK AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABEEZ ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMOR ABMQK ABNWP ABPLI ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACACY ACBXY ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACUDM ACULB ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFFNX AFGXO AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI C24 C6C CAG CCPQU COF CS3 CSCUP D-I DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GROUPED_DOAJ GRRUI GUQSH GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M2O M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 X7M YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAFWJ AASML AAYXX ABDBE ABFSG ACSTC ADHKG AEZWR AFFHD AFHIU AFPKN AGQPQ AHPBZ AHWEU AIXLP AYFIA CITATION PHGZM PHGZT PJZUB PPXIY RPM CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 7S9 L.6 5PM
ID	FETCH-LOGICAL-c508t-64fdaf7de5c64567b758b46268acceaca54f24c50f6f3fe2c7fe583af5d7af0b3
IEDL.DBID	RSV
ISICitedReferencesCount	11
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000972872100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0171-5216 1432-1335
IngestDate	Tue Nov 04 02:06:17 EST 2025 Thu Oct 02 05:49:35 EDT 2025 Thu Sep 04 19:31:24 EDT 2025 Sat Oct 18 23:15:04 EDT 2025 Sun Jul 20 01:30:20 EDT 2025 Tue Nov 18 21:00:35 EST 2025 Sat Nov 29 02:55:45 EST 2025 Fri Feb 21 02:42:43 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	11
Keywords	Reactive oxygen species Nuclear erythroid-related factor-2 Malignant rhabdoid tumour Chemoresistance Apoptosis Glutathione
Language	English
License	2023. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c508t-64fdaf7de5c64567b758b46268acceaca54f24c50f6f3fe2c7fe583af5d7af0b3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://link.springer.com/10.1007/s00432-023-04734-x
PMID	37079050
PQID	2842694409
PQPubID	47182
PageCount	13
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_10374708 proquest_miscellaneous_3040440676 proquest_miscellaneous_2803964535 proquest_journals_2842694409 pubmed_primary_37079050 crossref_citationtrail_10_1007_s00432_023_04734_x crossref_primary_10_1007_s00432_023_04734_x springer_journals_10_1007_s00432_023_04734_x
PublicationCentury	2000
PublicationDate	2023-09-01
PublicationDateYYYYMMDD	2023-09-01
PublicationDate_xml	– month: 09 year: 2023 text: 2023-09-01 day: 01
PublicationDecade	2020
PublicationPlace	Berlin/Heidelberg
PublicationPlace_xml	– name: Berlin/Heidelberg – name: Germany – name: Heidelberg
PublicationTitle	Journal of cancer research and clinical oncology
PublicationTitleAbbrev	J Cancer Res Clin Oncol
PublicationTitleAlternate	J Cancer Res Clin Oncol
PublicationYear	2023
Publisher	Springer Berlin Heidelberg Springer Nature B.V
Publisher_xml	– name: Springer Berlin Heidelberg – name: Springer Nature B.V
References	Florea, Büsselberg (CR8) 2011; 3 Zhu (CR36) 2018; 144 Silva, Rocha, Kinker, Pelegrini, Menck (CR25) 2019; 9 Salatino (CR24) 2019; 2019 Bao (CR3) 2017; 56 Chen, Jungsuwadee, Vore, Butterfield, St Clair (CR6) 2007; 7 Sporn, Liby (CR27) 2012; 12 Sun (CR28) 2019; 9 Barrera (CR4) 2021; 10 Liu (CR15) 2016; 7 Ray, Huang, Tsuji (CR22) 2012; 24 Neuwelt (CR19) 2014; 61 Hayes, Dinkova-Kostova, Tew (CR12) 2020; 38 Halasi (CR10) 2013; 454 Ballatori (CR1) 2009; 390 Coyle, Slattery, Ennis, Osullivan, Zisterer (CR7) 2019; 55 No, Kim, Song (CR20) 2014; 19 Zhu (CR35) 2016; 10 Pasello (CR21) 2008; 68 Suzuki, Otsuki, Keleku-Lukwete, Yamamoto (CR29) 2016; 1 Tekautz (CR31) 2005; 23 Bansal, Simon (CR2) 2018; 217 Li (CR13) 2016; 11 Brozovic, Ambriović-Ristov, Osmak (CR5) 2010; 40 Magnano, Hannon Barroeta, Duffy, O'Sullivan, Zisterer (CR17) 2021; 427 Geller, Roth, Biegel (CR9) 2015; 20 Rocha, Kajitani, Quinet, Fortunato, Menck (CR23) 2016; 7 Liou, Storz (CR14) 2010; 44 Marullo (CR18) 2013; 8 Singh (CR26) 2016; 11 Tagde, Singh, Kang, Reynolds (CR30) 2014; 4 Xie (CR34) 2022; 11 Traverso (CR33) 2013; 2013 Tonelli, Chio, Tuveson (CR32) 2018; 29 Hannon Barroeta, Magnano, O'Sullivan, Zisterer (CR11) 2022; 32 Liu, Sun, Zhang, Wang, Zheng (CR16) 2022; 36 A Brozovic (4734_CR5) 2010; 40 JI Geller (4734_CR9) 2015; 20 A Singh (4734_CR26) 2016; 11 A Salatino (4734_CR24) 2019; 2019 A Bansal (4734_CR2) 2018; 217 MB Sporn (4734_CR27) 2012; 12 M Pasello (4734_CR21) 2008; 68 R Marullo (4734_CR18) 2013; 8 H Zhu (4734_CR35) 2016; 10 Z Zhu (4734_CR36) 2018; 144 MM Silva (4734_CR25) 2019; 9 S Xie (4734_CR34) 2022; 11 AJ Neuwelt (4734_CR19) 2014; 61 Y Liu (4734_CR15) 2016; 7 Y Chen (4734_CR6) 2007; 7 Q Li (4734_CR13) 2016; 11 S Magnano (4734_CR17) 2021; 427 CR Rocha (4734_CR23) 2016; 7 P Hannon Barroeta (4734_CR11) 2022; 32 A Tagde (4734_CR30) 2014; 4 G-Y Liou (4734_CR14) 2010; 44 M Halasi (4734_CR10) 2013; 454 PD Ray (4734_CR22) 2012; 24 X Sun (4734_CR28) 2019; 9 M Suzuki (4734_CR29) 2016; 1 N Ballatori (4734_CR1) 2009; 390 C Tonelli (4734_CR32) 2018; 29 TM Tekautz (4734_CR31) 2005; 23 G Barrera (4734_CR4) 2021; 10 JH No (4734_CR20) 2014; 19 T Liu (4734_CR16) 2022; 36 R Coyle (4734_CR7) 2019; 55 AM Florea (4734_CR8) 2011; 3 N Traverso (4734_CR33) 2013; 2013 JD Hayes (4734_CR12) 2020; 38 L Bao (4734_CR3) 2017; 56
References_xml	– volume: 3 start-page: 1351 issue: 1 year: 2011 end-page: 1371 ident: CR8 article-title: Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects publication-title: Cancer doi: 10.3390/cancers3011351 – volume: 23 start-page: 1491 year: 2005 end-page: 1499 ident: CR31 article-title: Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.187 – volume: 68 start-page: 6661 year: 2008 end-page: 6668 ident: CR21 article-title: Overcoming glutathione S-transferase P1–related cisplatin resistance in osteosarcoma publication-title: Can Res doi: 10.1158/0008-5472.CAN-07-5840 – volume: 9 start-page: 17639 year: 2019 ident: CR25 article-title: The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells publication-title: Sci Rep doi: 10.1038/s41598-019-54065-6 – volume: 44 start-page: 479 year: 2010 end-page: 496 ident: CR14 article-title: Reactive oxygen species in cancer publication-title: Free Radic Res doi: 10.3109/10715761003667554 – volume: 8 start-page: e81162 year: 2013 end-page: e81162 ident: CR18 article-title: Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions publication-title: PLoS ONE doi: 10.1371/journal.pone.0081162 – volume: 11 start-page: 3214 year: 2016 end-page: 3225 ident: CR26 article-title: Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors publication-title: ACS Chem Biol doi: 10.1021/acschembio.6b00651 – volume: 19 start-page: 111 year: 2014 end-page: 117 ident: CR20 article-title: Targeting nrf2 signaling to combat chemoresistance publication-title: J Cancer Prev doi: 10.15430/JCP.2014.19.2.111 – volume: 10 start-page: 510 issue: 4 year: 2021 ident: CR4 article-title: Control of oxidative stress in cancer chemoresistance: spotlight on Nrf2 role publication-title: Antioxidants (basel) doi: 10.3390/antiox10040510 – volume: 29 start-page: 1727 year: 2018 end-page: 1745 ident: CR32 article-title: Transcriptional regulation by Nrf2 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2017.7342 – volume: 7 start-page: 42740 year: 2016 end-page: 42761 ident: CR15 article-title: Cancer drug resistance: redox resetting renders a way publication-title: Oncotarget doi: 10.18632/oncotarget.8600 – volume: 36 year: 2022 ident: CR16 article-title: Imbalanced GSH/ROS and sequential cell death publication-title: J Biochem Mol Toxicol doi: 10.1002/jbt.22942 – volume: 9 start-page: 754 year: 2019 ident: CR28 article-title: SIRT5 promotes cisplatin resistance in ovarian cancer by suppressing DNA damage in a ROS-dependent manner via regulation of the Nrf2/HO-1 pathway publication-title: Front Oncol doi: 10.3389/fonc.2019.00754 – volume: 55 start-page: 191 year: 2019 end-page: 202 ident: CR7 article-title: The XIAP inhibitor embelin sensitises malignant rhabdoid tumour cells to TRAIL treatment via enhanced activation of the extrinsic apoptotic pathway publication-title: Int J Oncol – volume: 11 start-page: 474 year: 2016 end-page: 480 ident: CR13 article-title: The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine publication-title: Oncol Lett doi: 10.3892/ol.2015.3879 – volume: 217 start-page: 2291 year: 2018 end-page: 2298 ident: CR2 article-title: Glutathione metabolism in cancer progression and treatment resistance publication-title: J Cell Biol doi: 10.1083/jcb.201804161 – volume: 2019 start-page: 3461251 year: 2019 ident: CR24 article-title: H-Ferritin affects cisplatin-induced cytotoxicity in ovarian cancer cells through the modulation of ROS publication-title: Oxid Med Cell Longev doi: 10.1155/2019/3461251 – volume: 427 start-page: 115646 year: 2021 ident: CR17 article-title: Cisplatin induces autophagy-associated apoptosis in human oral squamous cell carcinoma (OSCC) mediated in part through reactive oxygen species publication-title: Toxicol Appl Pharmacol doi: 10.1016/j.taap.2021.115646 – volume: 390 start-page: 191 year: 2009 end-page: 214 ident: CR1 article-title: Glutathione dysregulation and the etiology and progression of human diseases publication-title: Biol Chem doi: 10.1515/BC.2009.033 – volume: 56 start-page: 1543 year: 2017 end-page: 1553 ident: CR3 article-title: ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells publication-title: Mol Carcinog doi: 10.1002/mc.22615 – volume: 10 start-page: 1885 year: 2016 end-page: 1895 ident: CR35 article-title: Molecular mechanisms of cisplatin resistance in cervical cancer publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S106412 – volume: 7 start-page: 147 year: 2007 end-page: 156 ident: CR6 article-title: Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues publication-title: Mol Interv doi: 10.1124/mi.7.3.6 – volume: 40 start-page: 347 year: 2010 end-page: 359 ident: CR5 article-title: The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin publication-title: Crit Rev Toxicol doi: 10.3109/10408441003601836 – volume: 32 start-page: 100584 year: 2022 ident: CR11 article-title: Evaluation of targeting autophagy for the treatment of malignant rhabdoid tumours publication-title: Cancer Treat Res Commun doi: 10.1016/j.ctarc.2022.100584 – volume: 2013 year: 2013 ident: CR33 article-title: Role of glutathione in cancer progression and chemoresistance publication-title: Oxid Med Cell Longev doi: 10.1155/2013/972913 – volume: 24 start-page: 981 year: 2012 end-page: 990 ident: CR22 article-title: Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling publication-title: Cell Signal doi: 10.1016/j.cellsig.2012.01.008 – volume: 454 start-page: 201 year: 2013 end-page: 208 ident: CR10 article-title: ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors publication-title: Biochem J doi: 10.1042/BJ20130282 – volume: 12 start-page: 564 year: 2012 end-page: 571 ident: CR27 article-title: NRF2 and cancer: the good, the bad and the importance of context publication-title: Nat Rev Cancer doi: 10.1038/nrc3278 – volume: 38 start-page: 167 year: 2020 end-page: 197 ident: CR12 article-title: Oxidative stress in cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.06.001 – volume: 1 start-page: 29 year: 2016 end-page: 36 ident: CR29 article-title: Overview of redox regulation by Keap1–Nrf2 system in toxicology and cancer publication-title: Curr Opin Toxicol doi: 10.1016/j.cotox.2016.10.001 – volume: 11 start-page: 629 year: 2022 end-page: 638 ident: CR34 article-title: Analysis on diagnosis and treatments of 16 cases of extracranial malignant rhabdoid tumor in children publication-title: Transl Cancer Res doi: 10.21037/tcr-21-2548 – volume: 61 start-page: 120 year: 2014 end-page: 127 ident: CR19 article-title: Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.24602 – volume: 144 start-page: 93 year: 2018 end-page: 104 ident: CR36 article-title: Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis publication-title: J Neurochem doi: 10.1111/jnc.14250 – volume: 20 start-page: 199 year: 2015 end-page: 216 ident: CR9 article-title: Biology and treatment of rhabdoid tumor publication-title: Crit Rev Oncog doi: 10.1615/CritRevOncog.2015013566 – volume: 4 year: 2014 ident: CR30 article-title: The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma publication-title: Blood Cancer J doi: 10.1038/bcj.2014.45 – volume: 7 start-page: 48081 year: 2016 end-page: 48092 ident: CR23 article-title: NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells publication-title: Oncotarget doi: 10.18632/oncotarget.10129 – volume: 36 year: 2022 ident: 4734_CR16 publication-title: J Biochem Mol Toxicol doi: 10.1002/jbt.22942 – volume: 12 start-page: 564 year: 2012 ident: 4734_CR27 publication-title: Nat Rev Cancer doi: 10.1038/nrc3278 – volume: 8 start-page: e81162 year: 2013 ident: 4734_CR18 publication-title: PLoS ONE doi: 10.1371/journal.pone.0081162 – volume: 29 start-page: 1727 year: 2018 ident: 4734_CR32 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2017.7342 – volume: 4 year: 2014 ident: 4734_CR30 publication-title: Blood Cancer J doi: 10.1038/bcj.2014.45 – volume: 38 start-page: 167 year: 2020 ident: 4734_CR12 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.06.001 – volume: 10 start-page: 1885 year: 2016 ident: 4734_CR35 publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S106412 – volume: 56 start-page: 1543 year: 2017 ident: 4734_CR3 publication-title: Mol Carcinog doi: 10.1002/mc.22615 – volume: 44 start-page: 479 year: 2010 ident: 4734_CR14 publication-title: Free Radic Res doi: 10.3109/10715761003667554 – volume: 10 start-page: 510 issue: 4 year: 2021 ident: 4734_CR4 publication-title: Antioxidants (basel) doi: 10.3390/antiox10040510 – volume: 20 start-page: 199 year: 2015 ident: 4734_CR9 publication-title: Crit Rev Oncog doi: 10.1615/CritRevOncog.2015013566 – volume: 7 start-page: 42740 year: 2016 ident: 4734_CR15 publication-title: Oncotarget doi: 10.18632/oncotarget.8600 – volume: 24 start-page: 981 year: 2012 ident: 4734_CR22 publication-title: Cell Signal doi: 10.1016/j.cellsig.2012.01.008 – volume: 390 start-page: 191 year: 2009 ident: 4734_CR1 publication-title: Biol Chem doi: 10.1515/BC.2009.033 – volume: 7 start-page: 48081 year: 2016 ident: 4734_CR23 publication-title: Oncotarget doi: 10.18632/oncotarget.10129 – volume: 11 start-page: 629 year: 2022 ident: 4734_CR34 publication-title: Transl Cancer Res doi: 10.21037/tcr-21-2548 – volume: 9 start-page: 17639 year: 2019 ident: 4734_CR25 publication-title: Sci Rep doi: 10.1038/s41598-019-54065-6 – volume: 217 start-page: 2291 year: 2018 ident: 4734_CR2 publication-title: J Cell Biol doi: 10.1083/jcb.201804161 – volume: 11 start-page: 3214 year: 2016 ident: 4734_CR26 publication-title: ACS Chem Biol doi: 10.1021/acschembio.6b00651 – volume: 1 start-page: 29 year: 2016 ident: 4734_CR29 publication-title: Curr Opin Toxicol doi: 10.1016/j.cotox.2016.10.001 – volume: 11 start-page: 474 year: 2016 ident: 4734_CR13 publication-title: Oncol Lett doi: 10.3892/ol.2015.3879 – volume: 7 start-page: 147 year: 2007 ident: 4734_CR6 publication-title: Mol Interv doi: 10.1124/mi.7.3.6 – volume: 68 start-page: 6661 year: 2008 ident: 4734_CR21 publication-title: Can Res doi: 10.1158/0008-5472.CAN-07-5840 – volume: 55 start-page: 191 year: 2019 ident: 4734_CR7 publication-title: Int J Oncol – volume: 23 start-page: 1491 year: 2005 ident: 4734_CR31 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.187 – volume: 2013 year: 2013 ident: 4734_CR33 publication-title: Oxid Med Cell Longev doi: 10.1155/2013/972913 – volume: 40 start-page: 347 year: 2010 ident: 4734_CR5 publication-title: Crit Rev Toxicol doi: 10.3109/10408441003601836 – volume: 9 start-page: 754 year: 2019 ident: 4734_CR28 publication-title: Front Oncol doi: 10.3389/fonc.2019.00754 – volume: 3 start-page: 1351 issue: 1 year: 2011 ident: 4734_CR8 publication-title: Cancer doi: 10.3390/cancers3011351 – volume: 2019 start-page: 3461251 year: 2019 ident: 4734_CR24 publication-title: Oxid Med Cell Longev doi: 10.1155/2019/3461251 – volume: 427 start-page: 115646 year: 2021 ident: 4734_CR17 publication-title: Toxicol Appl Pharmacol doi: 10.1016/j.taap.2021.115646 – volume: 454 start-page: 201 year: 2013 ident: 4734_CR10 publication-title: Biochem J doi: 10.1042/BJ20130282 – volume: 144 start-page: 93 year: 2018 ident: 4734_CR36 publication-title: J Neurochem doi: 10.1111/jnc.14250 – volume: 61 start-page: 120 year: 2014 ident: 4734_CR19 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.24602 – volume: 19 start-page: 111 year: 2014 ident: 4734_CR20 publication-title: J Cancer Prev doi: 10.15430/JCP.2014.19.2.111 – volume: 32 start-page: 100584 year: 2022 ident: 4734_CR11 publication-title: Cancer Treat Res Commun doi: 10.1016/j.ctarc.2022.100584
SSID	ssj0017572
Score	2.4394073
Snippet	Purpose Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated... Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very... PurposeMalignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated... PURPOSE: Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated...
SourceID	pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	8379
SubjectTerms	Acetylcysteine antioxidant activity Antioxidants Antioxidants - pharmacology Apoptosis Buthionine Sulfoximine Cancer Research Cancer therapies cancer therapy Cell Line, Tumor Central nervous system Chemoresistance Chemotherapy Child childhood Children Cisplatin Cisplatin - pharmacology drug therapy Glutathione Glutathione - metabolism Hematology Humans Internal Medicine Malignancy Medicine Medicine & Public Health neoplasms NF-E2-Related Factor 2 - metabolism Oncology Oxidative stress prognosis Reactive oxygen species Reactive Oxygen Species - metabolism Rhabdoid Tumor - drug therapy siRNA transcription factors Tumors
SummonAdditionalLinks	– databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED9Bh9BeGN8EBjISb2Atje04fUIMbewBqokv7S1y7JhFYmnXtFP__N25bqYybS88RYovsZ07n-9y598BvJPox4qqGHElneKyRjEu0PPgWmXeS-8yEcB0fn_V43FxcjI6jj_cuphWudaJQVG7iaV_5HuoRunQJbojH6fnnKpGUXQ1ltC4C1uEVCYHsLV_MD7-3scRtArlmwgUBl2uYR6PzYTDcwGNjuOexVOpheTLza3pmr15PW3yn9hp2JIOd_53Mg_hQTRG2aeV9DyCO3X7GO5_i-H2J2BQiBjlH7KJZ2gpsvHMZ3tffhwxQ0mSy8bhla3AoFnTMtt0U8qtaxk68WSYokTR_TM09v9Qxg2bnZoKtahj88UZ9t49hV-HBz8_H_FYk4FbNOXmPEf-Ga9drWyOtpeu0N-oJHpFhbEWlbhR0mcSaX3uha8zq32tCmG8ctr4tBLPYNBO2voFsNyj8VAJ6wrnpE9HRuEnqSptNfZQD4sEhmt2lDYCllPdjL9lD7UcWFgiC8vAwnKZwPv-mekKruNW6t01e8q4dLvyijcJvO2bcdFRJMW09WRBNKkY4fyFuplGoHrEt-Q6T-D5SnD6IQnCJUxVmkCxIVI9AYF-b7a0zWkA_6ZznVKn-HU-rKXvauw3T_Xl7VN9BdtZWAmUPLcLg_lsUb-Ge_Zi3nSzN3FVXQLjvypJ priority: 102 providerName: ProQuest
Title	The role of the Nrf2/GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours
URI	https://link.springer.com/article/10.1007/s00432-023-04734-x https://www.ncbi.nlm.nih.gov/pubmed/37079050 https://www.proquest.com/docview/2842694409 https://www.proquest.com/docview/2803964535 https://www.proquest.com/docview/3040440676 https://pubmed.ncbi.nlm.nih.gov/PMC10374708
Volume	149
WOSCitedRecordID	wos000972872100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1432-1335 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0017572 issn: 0171-5216 databaseCode: 7X7 dateStart: 20230101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central (ProQuest) customDbUrl: eissn: 1432-1335 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0017572 issn: 0171-5216 databaseCode: BENPR dateStart: 20230101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 1432-1335 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0017572 issn: 0171-5216 databaseCode: 8C1 dateStart: 20230101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1432-1335 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0017572 issn: 0171-5216 databaseCode: M2O dateStart: 20230101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Standard Collection customDbUrl: eissn: 1432-1335 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017572 issn: 0171-5216 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BixAXypvQsjISN7DIxnbsHKFq6YEuVQvV3iLHDxqJZqvNLurPZ-xNgpY-JLhklc3kYXvs-UYz8xngLUc_llWqoIJbQblDNVboeVApMu-5txmLZDqnX-RkoqbT4qgrCmv7bPc-JBlX6qHYLbLHUbQxNOWScYrIcRPNnQrT8fjkdIgdSBG3bApEMOhmjfOuVOb6Z6yboysY82qq5F_x0miG9rf-rwGP4GEHO8nHlZ48hjuueQL3D7vA-lPQqC4kZBqSmSeICclk7rMPn08OiA7pkJe1xV-yon0mdUNM3V6ELLqGoLseICjqTvj_HGH9j5BbQ-ZnusL10pLF8hzf3j6D7_t733YPaLf7AjUI2hY0x5HSXlonTI4oS1boWVQc_R-ljcHlWgvuM46yPvfMu8xI74Ri2gsrtU8r9hw2mlnjXgLJPcKEihmrrOU-LbTIC15V0kh8gxurBMb9IJSmoyYPO2T8LAdS5dh3JfZdGfuuvEzg3XDPxYqY41bpnX5sy26StiVa5lDHix5uAm-Gyzi9QsxEN262DDIpK7D9TNwsw3AhxKfkMk_gxUpdhk9igYEwFWkCak2RBoFA771-panPIs13qODkMsXeed_r059vv7mpr_5NfBseZFElQ9rcDmws5kv3Gu6ZX4u6nY_grpzKeFR4VLvjEWx-2pscHePZYfZ1FGfeb_WTJLw
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgoAL74ehwCLBiVp1vGuvc0AIFUqqphESBfVm1utdaok6wU4g_Cl-IzPrRxWq9tYDp0jxxN71fjM7k535BuCFwDiWZ8nQj0Qe-cIgjBOMPHwZhdYKm4fckel8GcvJJDk8HH5cgz9dLQylVXY20RnqfKrpP_ItNKNUdInhyJvZD5-6RtHpatdCo4HFnvn9C0O2-vXuO1zfl2G48_5ge-S3XQV8jc7I3I9xBMrK3EQ6Ru9BZugxZwL9-kRpjWZIRcKGAmVtbLk1oZbWRAlXNsqlskHG8b6X4DIx2VGwl2z3KSW4E7tmUURBgwHeIG6LdFypnuO-83GH9AMhufCXqxvhKe_2dJLmPye1bgPcufm_vbpbcKN1tdnbRjduw5op78DV_TaZ4C4oVBFG2ZVsahn6wWxS2XDrw6cRU5QCuixy_GQN1TUrSqaLekaZgyWrTE1uN-oLfX-Mocw3yidi1ZHKcI_I2XxxjE-v78HnC5ngfVgvp6V5CCy26BplXOdJngsbDFWES5BlUkt8ghkkHgy65U91S8dOXUG-pz2RtINMipBJHWTSpQev-t_MGjKSc6U3OjikrWGq0xMsePC8v4wmhc6JVGmmC5IJ-BDnz6OzZTgaf7xLLGMPHjRA7YfEiXUxiAIPkhUI9wJEab56pSyOHLU5Va0KGeDb2ezQfjL2s6f66PypPoNro4P9cTrenew9huuh00JKE9yA9Xm1ME_giv45L-rqqdNnBl8vWgv-AkOyiXE
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgiouvB-BAkaCE1ibje04e0AItSytWlaVeKi31HFsGolml2QXlr_Gr2PsPKqlam89cIqUeBM7-ea1_mYG4AXHOJZlyYgKngvKDcI4wciDShFZy20eMV9M5-u-nEySw8PRwRr86XJhHK2y04leUedT7f4jH6AadUmXGI4MbEuLONgev539oK6DlNtp7dppNBDZM79_YfhWv9ndxm_9MorG7z9v7dC2wwDV6JjMaYyzUVbmRugYPQmZofeccfTxE6U1qiQluI04jrWxZdZEWlojEqasyKWyYcbwvlfgqmSIYpelvtXTS9Aq-8ZRrhwNBnvDuE3Y8Wl7vg4eRWtJQy4Zp8tVo3jG0z1L2Pxn19Ybw_HN__k13oIbrQtO3jUycxvWTHkHNj62JIO7oFB0iGNdkqkl6B-TSWWjwYdPO0Q5auiyyPFImhLYpCiJLuqZYxSWpDK1c8dRjtz5EwxxvjmeEamOVYa2IyfzxQk-vb4HXy5lgfdhvZyW5iGQ2KLLlDGdJ3nObThSAj9Hlkkt8QlmmAQw7KCQ6rZMu-sW8j3tC0x7-KQIn9TDJ10G8Kr_zawpUnLh6M0OGmmrsOr0FBcBPO8vo6px-0eqNNOFGxOyEa6fifPHMDQKeJdYxgE8aEDbT4m5aoyhCANIVuDcD3ClzlevlMWxL3nuslm5DPHtvO6Qfzr385f66OKlPoMNBH-6vzvZewzXIy-Qjj24CevzamGewDX9c17U1VMv2gSOLlsI_gKjjJI2
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+role+of+the+Nrf2%2FGSH+antioxidant+system+in+cisplatin+resistance+in+malignant+rhabdoid+tumours&rft.jtitle=Journal+of+cancer+research+and+clinical+oncology&rft.au=Hannon+Barroeta%2C+Patricia&rft.au=O%E2%80%99Sullivan%2C+Maureen+J.&rft.au=Zisterer%2C+Daniela+M.&rft.date=2023-09-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0171-5216&rft.eissn=1432-1335&rft.volume=149&rft.issue=11&rft.spage=8379&rft.epage=8391&rft_id=info:doi/10.1007%2Fs00432-023-04734-x&rft.externalDocID=10_1007_s00432_023_04734_x
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0171-5216&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0171-5216&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0171-5216&client=summon